Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma

Archives of Ophthalmology

Volumn 127, Issue 2, 2009, Pages 173-178

  Robin, Alan L ^a,f   Suan, Eric P ^b   Sjaarda, Raymond N ^c   Callanan, David G ^d   Defaller, Joseph ^e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Retina Care Center   (United States)

^c TEXAS RETINA ASSOCIATES   (United States)

^d ALCON RESEARCH LTD   (United States)

^e IOP Research Team

^f Ste 333 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANECORTAVE; APRACLONIDINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PILOCARPINE; STEROID; TRIAMCINOLONE ACETONIDE; ANTIHYPERTENSIVE AGENT; GLUCOCORTICOID; PREGNANE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIABETIC MACULAR EDEMA; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA CYSTOID EDEMA; TOPICAL ANESTHESIA; TREATMENT DURATION; UVEITIS; VISUAL ACUITY; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; DRUG EFFECT; INJECTION; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PROSPECTIVE STUDY; RETINA DISEASE; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PREGNADIENEDIOLS; PROSPECTIVE STUDIES; RETINAL DISEASES; TONOMETRY, OCULAR; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 60549091968     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2008.595     Document Type: Article

References (19)

1. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218-245.
2. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112(4):593-598.
3. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone ace-tonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740-743.
4. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110(12):2372-2385.
5. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs. 1997;6(12):1867-1877.
6. McNatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Phar-macol Ther. 1999;15(5):413-423.
7. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42(1):283-290.
8. DeFaller JM, Clarke AF. A new pharmacologic treatment for angiogenesis. In: Taylor HR, ed. Pterygium.The Hague, The Netherlands: Kugler Publications; 2000:159-181.
9. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina. 2003;23(1):14-23.
10. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics II: the effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70:492-499.
11. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics I: the effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.
12. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90(8):999-1003.
13. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye. 2007;21(3):317-320.
14. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III, Miller M. Intraocularconcentration and pharmacokinetics of triamcinolone acetonide after a single intravit-real injection. Ophthalmology. 2003;110(4):681-686.
15. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol. 2004;138(1):158-160.
16. Wilson K, McCartneyMD, Miggans ST, Clark AF. Dexamethasone induced ultra-structural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783-793.
17. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1994;35(1):281-294.
18. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84(2):275-284.
19. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18(5):629-667.